The Second Act of Biotech
Tip Ranks·- Pfizer and Moderna are heavily investing in new medical fields such as obesity treatments and personalized cancer vaccines following the post-COVID revenue decline. - Pfizer completed its acquisition of Metsera for approximately $7 billion to secure the ultra-long-acting GLP-1 receptor agonist berobenatide. - Pfizer is advancing an extensive obesity program that includes 10 Phase 3 trials and over 20 overall studies to improve treatment convenience and efficacy.Moderna declines 3% in regular trading after downgrade, dilution concerns
US Stock Market Update·Moderna falls 4% as Rothschild Redburn downgrades on valuation concerns
US Stock Market Update·Stock Futures Trade Mixed as Treasury Yields Ease
Tip Ranks·- U.S. stock futures traded mixed on September 3, 2026, as the 10-year Treasury yield eased to around 4.752% following recent multi-year highs. - Major stock indices had previously snapped a three-day losing streak on Wednesday, driven by a rebound after a weak start to September. - Pre-market trading featured notable stock movements, including a 24% rally for Snowflake following strong Q2 results and a 4% decline for Broadcom on disappointing guidance.